# TRL for BIRAC SBIRI and BIPP: matching your stage to the scheme

URL: https://zernyxhub.com/blog/trl-for-birac-sbiri-bipp
Author: Dr. Abhay Tharmatt, Research Scientist, R&D, Zernyx Innovations
Published: 2026-11-02
Category: Technology readiness

> BIRAC BIPP or SBIRI? Match your TRL to the right scheme: SBIRI ends at TRL 6, BIPP at TRL 7 or above. The 2025 funding pattern, royalty and a worked example.

**Short answer:** BIRAC's SBIRI and BIPP schemes, run together as the i4 programme, split at TRL 6. SBIRI projects must end at TRL 6 or below. BIPP projects must end at TRL 7 or above. Under the April 2025 guidelines, a start-up without a prior BIRAC grant can get up to 100% grant below ₹50 lakh; established companies get up to 70%.

For a biotech company applying to BIRAC, one number decides which form to fill: the TRL at which the project will end. BIRAC runs two schemes for company-led product development under its i4 programme. The Small Business Innovation Research Initiative (SBIRI) covers the stretch up to TRL 6. The Biotechnology Industry Partnership Programme (BIPP) starts where SBIRI stops, with projects that end at TRL 7 or above.

Apply to the wrong one and the proposal fails screening, however good the science. This post sets out the rules from BIRAC's scheme guidelines of April 2025 and shows how to place a project.

## What are SBIRI and BIPP?

BIRAC's [i4 programme page](https://birac.nic.in/birac_i4.php) describes both as schemes to help start-ups, companies and LLPs take ideas past proof of concept through validation, scale-up, demonstration and pre-commercialisation.

| | SBIRI | BIPP |
|---|---|---|
| Purpose | Early-stage product and technology development by industry | High-risk, transformational technology or process development |
| End TRL | TRL 6 or below | TRL 7 or above |
| Typical work | Initial validation and prototype, building on proof of principle | Validation, demonstration, pre-commercialisation, clinical or field trials, shared facilities |
| Applicant | Company or LLP, alone or in consortium | Company or LLP, alone or in consortium |
| Academic partner | Optional | Optional |
| Project cost ceiling | None | None |
| Royalty | 5% of annual net sales until equal to grant | 5% of annual net sales until equal to grant (none for Category IV) |

Sources: [SBIRI scheme guidelines](https://birac.nic.in/webcontent/1745298212_SBIRI_scheme_guidelines_16_04_2025.pdf) and [BIPP scheme guidelines](https://www.birac.nic.in/webcontent/1745298172_BIPP_scheme_guidelines_16_04_2025.pdf), both dated 16 April 2025 in their file names.

**Where SBIRI ends and BIPP begins**
- TRL 3: Proof of principle with data
- TRL 4: Lab validation
- TRL 5: Validation in a relevant setting
- TRL 6: Prototype demonstrated; SBIRI's limit
- TRL 7: Operational demonstration; BIPP's floor
- TRL 8: Qualified, trials complete
(BIPP ends at TRL 7 or up: TRL 7 to TRL 8)

## How do you decide where your project ends?

Look at the last experiment in your plan, not the first. The scheme follows the end point.

At the bench, the question is concrete. What will exist on the last day of the project, and where will it have been tested?

- A purified enzyme with activity data at lab scale, a diagnostic assay run on banked samples, a device prototype on a test rig: these usually end at TRL 4 to 6. That is SBIRI.
- A vaccine candidate in a clinical trial, a crop line in multi-location field trials, a process running at pilot or demonstration scale in the target setting: these usually end at TRL 7 or above. That is BIPP.

BIRAC's TRL wording differs by sector, so use the definition that fits your product. Our [TRL for biotech](https://zernyxhub.com/blog/trl-for-biotech) post explains the sector versions.

Two more filters apply. SBIRI does not support concepts or exploratory ideas without a proper proof of principle, or proposals without preliminary data. BIPP does not support incremental development or narrow support for a single event in the commercialisation chain, Category I excludes minor-use products, and every project must generate novel IP.

## What does BIPP cover?

BIPP has four categories in its 2025 guidelines:

1. Category I: translational work on major national needs with no assured market, such as vaccines for major epidemics or low-cost equivalents of imported medical devices.
2. Category II: accelerated development of futuristic technologies, such as synthetic biology, stem cells or genomics-based diagnostics.
3. Category III: product evaluation and validation, split into IIIA for clinical trials and IIIB for multi-location agricultural field trials.
4. Category IV: shared facilities such as BSL-3 laboratories, GMP facilities and genomics centres, funded at up to 50% with no royalty.

## How much funding do the schemes give?

The April 2025 guidelines use the same funding pattern for SBIRI and BIPP Categories I to III.

| Applicant | Budget below ₹50 lakh | Budget of ₹50 lakh or more |
|---|---|---|
| Start-up (under 10 years old) with no prior BIRAC grant | Up to 100% grant | ₹50 lakh plus up to 70% of the excess |
| Start-up with a prior BIRAC grant, or company over 10 years old | Up to 70%; company pays at least 30% | Up to 70%; company pays at least 30% |
| Central or state government institution (as collaborator) | Up to 100% | Up to 100% |

Two cautions. First, each guideline also refers to a one-time grant "subject to a maximum of Rs. 50 lakhs" for first-time start-ups, which sits awkwardly with the formula above. Second, the i4 web page still shows older figures: 50% of the cost above ₹50 lakh for SBIRI, and a 50% cap for BIPP. Ask BIRAC which applies to the current call before you build the budget.

Money is released in four instalments: on signing, after the first technical milestone, after the second, and as a reimbursement on the project completion report. The company must put in its own share before each release.

## A worked example in rupees

The figures below are an illustration, using the April 2025 pattern.

A seven-year-old diagnostics company with no prior BIRAC grant plans an SBIRI project to take an assay from TRL 4 to TRL 6. Budget: ₹1,20,00,000.

- First ₹50,00,000: up to 100% grant, so ₹50,00,000.
- Excess of ₹70,00,000: up to 70%, so ₹49,00,000.
- Maximum BIRAC grant: ₹99,00,000. Company share: at least ₹21,00,000.

If BIRAC applies the ₹50 lakh one-time cap instead, the grant is ₹50,00,000 and the company funds ₹70,00,000. That ₹49 lakh gap is why the cap question matters.

Now the royalty. Say the company receives the full ₹99,00,000 and later sells the assay with net sales of ₹2,00,00,000 a year. At 5%, royalty is ₹10,00,000 a year, so the obligation ends after roughly ten years of sales at that level, when royalty paid equals the grant. Higher sales repay faster.

## How are proposals evaluated?

The SBIRI guidelines describe six stages. Check the BIPP guidelines and call for any differences in its route.

**How an SBIRI proposal is evaluated**
1. Eligibility check: Entity, ownership, facilities
2. Area Review Panel: Presentation to the sector panel
3. Site visit: Or online interaction
4. Technical Expert Committee: Scientific and technical review
5. Financial due diligence: For recommended proposals
6. Apex Committee: Final decision

BIRAC runs two regular calls a year, plus need-based calls. A company can hold at most two ongoing projects as primary applicant and two as collaborator. Applications go online through the BIRAC website, and the call closes at 17:30 on the last date.

## What evidence should the proposal carry?

For SBIRI, show the proof of principle you already have: dose-response curves, assay sensitivity on real samples, a working prototype on the bench. The panel wants to see that the project starts from data. For BIPP, show the validated prototype and the plan for the operational setting: trial protocols, field sites, regulatory approvals, scale-up batches.

In both, state the start and end TRL in BIRAC's sector definition, and tie each milestone to a measurable result. Our posts on [proving your TRL](https://zernyxhub.com/blog/trl-evidence) and on the [BIRAC BIG grant](https://zernyxhub.com/blog/birac-big-grant-trl) cover evidence for the earlier stages, and [TRL for BIRAC PACE](https://zernyxhub.com/blog/trl-for-birac-pace) covers academic-led projects.

## Common mistakes

- Choosing SBIRI because the grant share looks better, then writing milestones that reach TRL 7.
- Applying to BIPP with an incremental improvement to an existing product.
- Ignoring the royalty when modelling the business case.
- Building the budget on the i4 web page figures without checking the current guidelines.
- Claiming TRL 6 for a whole product when only one module has reached it.

The SBIRI and BIPP split is one of the cleaner designs in Indian grant funding, because the end TRL is the dividing line rather than company size. Where teams go wrong is at the boundary. A project that ends with a prototype tested in a relevant environment is TRL 6; one tested in the real setting is TRL 7. If you are unsure which side you sit on, the safer move is usually to plan an SBIRI project to TRL 6 and a follow-on BIPP project, though BIRAC's current call and its programme officers have the final word.

To check your starting level first, [TRL Pro](https://app.zernyxhub.com/trl-calculator) lets you enter your technology and get back a readiness level from TRL 1 to 9, assessed with Zernyx's own copyrighted framework (ZTRAF) across more than 60 technology domains and subdomains.

## Common questions

### What is the difference between SBIRI and BIPP?

SBIRI supports early-stage biotechnology product development by companies, with projects ending at TRL 6 or below. BIPP is BIRAC's advanced technology scheme for high-risk, transformational development, with projects ending at TRL 7 or above. Both are offered under BIRAC's i4 programme.

### Who can apply for SBIRI or BIPP?

A company incorporated under the Companies Act, 2013 or an LLP under the LLP Act, 2008, alone or in a consortium. At least 51% of a company's shares must be held by Indian citizens, and at least half of an LLP's partners must be Indian citizens. An academic partner is optional.

### Do SBIRI and BIPP grants carry a royalty?

Yes. Both April 2025 guidelines set a royalty of 5% of annual net sales of the product, from the first sale, until the royalty paid equals the grant disbursed. BIPP's infrastructure category, Category IV, carries no royalty.

### How much funding can a start-up get under SBIRI?

The April 2025 SBIRI guidelines give a start-up with no prior BIRAC grant up to 100% grant for a budget below ₹50 lakh, and ₹50 lakh plus up to 70% of the excess above that. The same document also refers to a one-time grant subject to a maximum of ₹50 lakh, so confirm the cap with BIRAC.

---

Published by Zernyx Hub. More: https://zernyxhub.com/llms.txt
